Last reviewed · How we verify
alogliptin and actoplus met
Alogliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and lower blood glucose, while metformin reduces hepatic glucose production and improves insulin sensitivity.
Alogliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and lower blood glucose, while metformin reduces hepatic glucose production and improves insulin sensitivity. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | alogliptin and actoplus met |
|---|---|
| Sponsor | The Fourth Affiliated Hospital of Zhejiang University School of Medicine |
| Drug class | DPP-4 inhibitor + biguanide combination |
| Target | DPP-4 enzyme; metformin acts on multiple targets including mitochondrial glycerophosphate dehydrogenase |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
This is a fixed-dose combination of a DPP-4 inhibitor and a biguanide. Alogliptin prevents the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), enhancing insulin secretion in response to meals. Metformin decreases hepatic gluconeogenesis and increases peripheral glucose uptake and utilization, addressing multiple pathways of hyperglycemia in type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Nasopharyngitis
- Headache
- Gastrointestinal disturbance
- Pancreatitis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: